0000874015-16-000144.txt : 20161114 0000874015-16-000144.hdr.sgml : 20161111 20161114185151 ACCESSION NUMBER: 0000874015-16-000144 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161109 FILED AS OF DATE: 20161114 DATE AS OF CHANGE: 20161114 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CROOKE STANLEY T CENTRAL INDEX KEY: 0000897667 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 161997271 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2016-11-09 0000874015 IONIS PHARMACEUTICALS INC IONS 0000897667 CROOKE STANLEY T C/O IONIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT CARLSBAD CA 92010 1 1 0 0 Chairman and CEO Common Stock 2016-11-09 2016-11-09 4 M 0 10000 10.29 A 35029 D Common Stock 2016-11-09 2016-11-09 4 S 0 10000 35.55 D 25029 D Common Stock 2016-11-09 2016-11-09 4 M 0 6259 10.29 A 31288 D Common Stock 2016-11-09 2016-11-09 4 S 0 6259 37.10 D 25029 D Common Stock 2016-11-09 2016-11-09 4 M 0 3741 7.25 A 28770 D Common Stock 2016-11-09 2016-11-09 4 S 0 3741 37.50 D 25029 D Common Stock 2016-11-09 2016-11-09 4 M 0 1000 10.29 A 3170 I By wife Common Stock 2016-11-09 2016-11-09 4 S 0 1000 35.10 D 2170 I By wife Common Stock 2016-11-09 2016-11-09 4 M 0 1000 10.29 A 3170 I By wife Common Stock 2016-11-09 2016-11-09 4 S 0 1000 37.25 D 2170 I By wife Common Stock 2016-11-10 2016-11-10 4 M 0 10000 7.25 A 35029 D Common Stock 2016-11-10 2016-11-10 4 S 0 10000 40.23 D 25029 D Common Stock 2016-11-10 2016-11-10 4 M 0 1000 10.29 A 3170 I By wife Common Stock 2016-11-10 2016-11-10 4 S 0 1000 42.22 D 2170 I By wife Common Stock 725391 I By trust Employee Stock Option (right to buy) 10.29 2016-11-09 2016-11-09 4 M 0 16259 0 D 2015-01-03 2018-01-02 Common Stock 16259 0 D Employee Stock Option (right to buy) 7.25 2016-11-09 2016-11-09 4 M 0 3741 0 D 2016-01-03 2019-01-02 Common Stock 3741 103462 D Employee Stock Option (right to buy) 10.29 2016-11-09 2016-11-09 4 M 0 2000 0 D 2015-01-03 2018-01-02 Common Stock 2000 6500 I By wife Employee Stock Option (right to buy) 7.25 2016-11-10 2016-11-10 4 M 0 10000 0 D 2016-01-03 2019-01-02 Common Stock 10000 93462 D Employee Stock Option (right to buy) 10.29 2016-11-10 2016-11-10 4 M 0 1000 0 D 2015-01-03 2018-01-02 Common Stock 1000 5500 I By wife Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. The sale was a result of shares owned. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.10 to $36.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.50, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2016. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.50, inclusive. The reporting person's wife undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.22 to $40.33, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) on this Form 4. /s/B. Lynne Parshall, attorney-in-fact 2016-11-11